Treating psoriasis with adalimumab
نویسندگان
چکیده
Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. Among the most successful strategies for treatment has been the use of biologic immunotherapies targeting tumor necrosis factor alpha (TNF). Recent research has evaluated the efficacy and safety of a new anti-TNF agent, adalimumab. Adalimumab is a human monoclonal antibody that is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of rheumatoid arthritis and psoriatic arthritis. Recently released data from large, randomized clinical trials suggests that adalimumab has significant efficacy for the treatment of chronic plaque psoriasis and is well tolerated. Thus, adalimumab seems to be a promising therapeutic approach for patients who suffer from moderate to severe plaque psoriasis.
منابع مشابه
Evaluation of COVID-19 incidence in psoriatic patients receiving Adalimumab
Background: Adalimumab is a highly human monoclonal antibody that binds to tumor necrosis factor, a key proinflammatory cytokine pathogenic in psoriasis. It considers an influential factor in controlling moderate to severe psoriasis. This study aimed to evaluate the impact of Adalimumab on COVID-19 incidence in patients with psoriasis. Methods: This cross-sectional study was performed at Baqiy...
متن کاملBenefits vs. side effects of Adalimumab treatment in Psoriasis/Psoriatic Arthritis
Psoriatic Arthritis (PsA) is a seronegative, inflammatory joint disease. In most patients with PSA, skin psoriasis precedes arthritis; however, the causality is multi-factorial and many aspects related to it remain unclear. Tumor necrosis factor (TNF) plays essential role in the pathogenesis of PsA and psoriasis. Hence, the selective inhibition of TNF-α leads to significant improvement of disea...
متن کاملLong-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the skin and joints. Patients with moderate to severe psoriasis constitute about 30% of the psoriasis population. Treatment of this group is challenging due to the long-term side effects, toxicities and inconvenience of conventional treatments such as phototherapy, methotrexate and cyclosporine. However, recent a...
متن کاملEfficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH
BACKGROUND The Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet (REACH) trial demonstrated that adalimumab was efficacious and well-tolerated for the treatment of hand and/or foot psoriasis through 28 weeks. OBJECTIVE To evaluate the effects of patient baseline characteristics on efficacy of adalimumab treatment of hand and/or foot ...
متن کاملTreatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation.
IMPORTANCE Nail psoriasis can be difficult to treat and has a significant effect on quality of life. Relatively few controlled trials evaluating treatments for nail psoriasis have been published. There is an unmet need for treatment recommendations to guide therapeutic decisions. OBJECTIVE To develop treatment recommendations for nail psoriasis from the Medical Board of the National Psoriasis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Therapeutics and Clinical Risk Management
دوره 4 شماره
صفحات -
تاریخ انتشار 2008